Drug intelligence / Profile preview

salbutamol + oxygen

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Inhalation
01

Overview

Salbutamol + oxygen is a combination therapy used primarily in the management of acute and severe respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other forms of bronchospasm. Salbutamol (also known as albuterol) is a short-acting beta-2 adrenergic receptor agonist that acts as a bronchodilator, relaxing bronchial smooth muscle to relieve airway obstruction and improve airflow. Oxygen therapy provides supplemental oxygen to correct or prevent hypoxemia, improving tissue oxygenation during acute respiratory distress. The combination is often administered via nebulization, where salbutamol is delivered in aerosolized form using oxygen as the driving gas. This approach can be particularly beneficial for patients with significant hypoxemia or those experiencing severe exacerbations of obstructive airway diseases. Clinical studies have shown that combining bronchodilators like salbutamol with supplemental oxygen can enhance exercise performance and reduce dyspnea more effectively than either treatment alone in patients with severe COPD[4][5].

02

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on salbutamol + oxygen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on salbutamol + oxygen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call